Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of Sickle cell disease within Medicaid programs.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of Sickle cell disease within Medicaid programs.
Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of Sickle cell disease within Medicaid programs. J Med Econ. 2013; 16(1):10-8.
View in:
PubMed
subject areas
Adolescent
Adolescent
Adult
Adult
Age Factors
Age Factors
Anemia, Sickle Cell
Anemia, Sickle Cell
Benzoates
Benzoates
Blood Transfusion
Blood Transfusion
Child
Child
Deferoxamine
Deferoxamine
Drug Utilization
Drug Utilization
Female
Female
Health Expenditures
Health Expenditures
Humans
Humans
Insurance Claim Review
Insurance Claim Review
Iron Chelating Agents
Iron Chelating Agents
Kaplan-Meier Estimate
Kaplan-Meier Estimate
Male
Male
Medicaid
Medicaid
Medication Adherence
Medication Adherence
Patient Preference
Patient Preference
Proportional Hazards Models
Proportional Hazards Models
Retrospective Studies
Retrospective Studies
Sex Factors
Sex Factors
Triazoles
Triazoles
United States
United States
authors with profiles
Grant H Skrepnek